Search

Displaying results 7721 - 7730 of 10000 in total
  1. Drug

    Matrix-M

    go.drugbank.com/drugs/DB16369
    Investigational

    Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.

  2. Drug

    Astegolimab

    go.drugbank.com/drugs/DB16386
    Investigational

    Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  3. Drug

    Pidacmeran

    go.drugbank.com/drugs/DB16401
    Investigational

    Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).

  4. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423]. … This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423].

  5. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].

  6. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow protocol[L30583].

  7. Drug

    Dociparstat sodium

    go.drugbank.com/drugs/DB16481
    Investigational

  8. Drug

    Novaferon

    go.drugbank.com/drugs/DB16483
    Investigational

  9. Drug

    Enpatoran

    go.drugbank.com/drugs/DB16501
    Investigational

    Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis … It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327).

  10. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19